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A B S T R A C T   
Intracranial hemorrhage (ICH) is the most feared complication of anticoagulation with a high mortality and morbidity. Before registration of a specific reversal agent 
for factor Xa inhibitors (FXa-I), international guidelines recommended prothrombin complex concentrate (PCC), which also is the specific reversal agent for vitamin K 
antagonists (VKA). In two contemporary cohorts, we compared clinical outcomes between patients with FXa-I and VKA related ICH treated with PCC between 2014 
and 2018. Primary outcome was effective hemostasis after 24 h, according to the International Society of Thrombosis and Hemostasis definition. Safety outcomes 
were defined as venous and arterial thromboembolic complications and death within 30 days. Thirty-six patients with FXa-I-ICH and 39 patients with VKA-ICH were 
available for analysis. Baseline characteristics were comparable between both groups, except for time from start of symptoms to presentation at the hospital. In the 
FXa-I-ICH cohort, 24 (73%) patients achieved effective hemostasis compared to 23 (62%) patients in the VKA-ICH cohort (crude odds ratio [OR] 1.62 [95%CI 
0.59–4.48], adjusted OR 1.45 [95%CI 0.44–4.83]). Eight (24%) patients with FXa-I-ICH deceased compared to 17 (45%) patients with VKA-ICH (crude OR 0.38 
[95%CI 0.14–1.24], adjusted OR 0.41 [95%CI 0.12–1.24]). In this observational cohort study, the outcome of ICH managed with PCC was similar in patients with 
FXa-I-ICH and in patients with VKA-ICH.  
1. Introduction 
Due to the high mortality and morbidity, intracranial hemorrhage 
(ICH) is the most feared complication in patients using anticoagulant 
drugs [1]. Almost half of patients die after ICH and two thirds of the 
survivors suffer from significant functional dependencies [2–4]. As a 
consequence anticoagulant related ICH is eminently the type of emer-
gency for which reversal of an oral anticoagulant is thought crucial to 
improve the outcome of the bleed [5]. Reported ICH incidences with 
use of direct oral anticoagulants (DOACs) are half of the reported ICH 
incidences with the use of vitamin K antagonists (VKA) [6,7]. In par-
allel, reported incidences of DOAC-related fatal bleeding are half that of 
VKA-related fatal bleeding [6,8]. 
Four-factor prothrombin complex concentrate (PCC) is a specific 
reversal agent for VKA and consists of the vitamin K dependent coa-
gulation factors II, VII, IX and X. Therefore, international guidelines 
recommend the use of PCC when immediate VKA reversal is indicated 
[9,10]. Upon regulatory approval of the DOACs, physicians were con-
cerned about the absence of a reversal agent, especially for patients 
with a high bleeding risk. Before the registration of andexanet alfa for 
reversal of direct factor Xa inhibitors (FXa-I), PCC was recommended by 
several guidelines as part of the management in patients with FXa-I 
related emergencies [11,12]. This recommendation was based on a 
randomized crossover study in healthy non-bleeding volunteers on 
rivaroxaban showing that administration of PCC immediately restored 
thrombin generation [13]. 
Importantly, the prognosis of FXa-I-ICH managed with PCC is un-
known, as well as whether its prognosis differs from the prognosis of 
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VKA-ICH managed with PCC. Since several clinical registries have 
suggested that PCC is effective and safe for FXa-I reversal, current 
clinical guidelines also suggest treatment with PCC for life-threatening 
FXa-I emergencies [9,14,15]. 
We compared the clinical outcomes of two contemporary cohorts of 
patients with ICH, either on a FXa-I or on a VKA, both managed with 
PCC. We hypothesized that the prognosis of the patients in both cohorts 
are similar. 
2. Methods 
2.1. Study population and design 
Participants in this study were selected from two Dutch observa-
tional studies: the DOAC emergency registry and the ROVAP cohort 
[20,21]. The DOAC emergency study consisted of 121 consecutively 
included patients who presented with a DOAC-related emergency be-
tween 2014 and 2018 [16]. The ROVAP cohort consisted of 100 con-
secutive patients that presented with a VKA related major bleeding 
between September 2014 and December 2015 for which PCC was ad-
ministered as a reversal agent [17]. For the present study, we included 
those patients who had an ICH and received PCC. All patients using 
direct factor Xa inhibitors or VKA were eligible, patients using dabi-
gatran were excluded.. The choice to use PCC and the choice of the PCC 
dose was at the discretion of the treating physician in both studies, as 
was the choice of adding other hemostatic measures to the ICH man-
agement. For management of DOAC emergencies, national guidelines in 
the Netherlands suggests PCC in a dose of 25–50 international units 
(IU)/kilogram (kg) and for management of VKA emergencies the PCC 
dose is based on the patient's weight and international normalized ratio 
(INR). 
In both cohorts data on medical history, anticoagulant use, ICH 
characteristics and concomitant medication use were collected by chart 
review, along with details on management of the bleed. ICH volume 
was measured centrally by one investigator (RB) using the ABC/2 score 
for intracerebral hemorrhage [23]. For subdural or epidural ICH, the 
diameter of the bleeding was measured. Volumes of subarachnoid he-
morrhages were not calculated. When in doubt, the volumes were 
discussed with an independent radiologist (LB), who was blinded for 
the cohort (DOAC or VKA) the patient belonged to. 
2.2. Clinical outcomes 
The definitions of clinical outcomes were identical in both cohorts. 
The efficacy outcome was effective hemostasis 24 h after presentation 
or PCC administration [16,17]. Effective hemostasis was defined ac-
cording to the ISTH criteria [18]. According to these criteria hemostasis 
can be classified as excellent, good or poor according to the site of 
bleeding (musculoskeletal, intracranial or other non-visible bleeding), 
wherein effective hemostasis is defined as either excellent or good he-
mostasis. The hemostatic classification of patients with intracranial 
bleeding can be either assessed by repeated imaging to evaluate he-
matoma expansion or by clinical evaluation on the neurological con-
dition after 24 h, assessed by neurological scores such as Glasgow Coma 
Score (GCS). Worsening of the neurological condition or cessation of 
treatment is considered as poor hemostasis [19]. 
In the DOAC emergency registry, effective hemostasis was evaluated 
by four site investigators and reviewed by the national coordinator (RB) 
of the study. In case of doubt, classification was made by consensus 
with the last author (MC) [18]. For the VKA cohort, effective hemos-
tasis had been evaluated by the national coordinator (MB) and, when in 
doubt, discussed with the last author (MC). 
Safety outcomes consisted of thromboembolic events and mortality 
up to 30 days after presentation. Thromboembolic events were defined 
as venous and arterial events comprising pulmonary embolism, deep 
vein thrombosis, myocardial infarction, transient ischemic attack, is-
chemic stroke and systemic embolisms. Patients were followed until 
30 days after inclusion or death. 
2.3. Statistical analysis 
Differences in continuous variables between patients of the DOAC 
cohort and the VKA cohort were evaluated using the independent 
sample t-test; variables with a skewed distribution were compared by 
the non-parametric Mann-Whitney U test. Chi-square tests were applied 
for comparing distributions of dichotomous data. 
The association between the different outcomes (efficacy and safety) 
and treatment (DOAC-I or VKA) were explored using logistic regression 
analyses. We adjusted for potential confounders by means of multiple 
logistic regression analyses in two different ways. First, all variables 
that were considered clinically relevant by the authors were joined in a 
full model. With the use of stepwise backward elimination (significance 
level to stay [SLS] in the model < 0.1), a final model, that always 
contained the variable anticoagulant treatment (VKA or DOAC), was 
derived. These variables in the model considered clinically relevant by 
the authors consisted of age, center, indication anticoagulation, ICH 
location, baseline GCS, hypertension, baseline systolic blood pressure, 
trauma, procedure, history of stroke, concomitant NSAID/antiplatelet 
use and cancer. 
The second model was derived by including those variables that had 
a p-value below 0.25 for both the relationship with the determinant 
(DOAC or VKA) and the outcome. In line with the first model, stepwise 
backward elimination (SLS  <  0.1) was applied. Variables with more 
than 30% missing values, were not taken into account as possible 
confounders. A p-value of less than 0.05 was considered to be statisti-
cally significant. All statistical analyses were performed using the SPSS 
package (version 26.0, Chicago, Illinois). 
3. Results 
3.1. Study population 
Of 221 patients, 36 (30%) of the DOAC emergency registry cohort 
and 39 (39%) patients of the ROVAP cohort had ICH and received PCC; 
these patients comprised our study population. All 36 DOAC-ICH pa-
tients were using factor-Xa inhibitors (from now on referred to as the 
“FXa-I-ICH”). Demographic and clinical characteristics of both cohorts 
are shown in Table 1. Most patients (36%) presented with an in-
tracerebral bleeding. The median intracerebral bleeding volume was 
15 ml (IQR 4–34) in the FXa-I-ICH compared to 22 ml (IQR 3–54) in the 
VKA-ICH cohort (p = 0.695). The median time from symptoms of ICH 
to presentation in the hospital was reported in 36 (48%) patients and 
was 135 min (IQR 71–253 min) for the FXa-I-ICH and 360 min (IQR 
116–1440 min) for the VKA-ICH cohort (p = 0.006). Bleeding man-
agement did not differ between both cohorts, except for the dose of PCC 
(Table 2). Patients in the FXa-I-ICH cohort were treated with a median 
dose of 50 IU/kg (IQR 50–50) and patients in the VKA-ICH cohort were 
treated with a median PCC dose of 20 IU/kg (IQR 20–25) (p  <  0.001). 
Thirty-three out of 39 patients in the VKA-ICH cohort also received 
vitamin K as part of the reversal management. 
3.2. Outcomes 
3.2.1. Efficacy 
Effective hemostasis after 24 h was not assessable in five patients of 
which three belonged to the FXa-I-ICH cohort and two belonged to the 
VKA-ICH cohort. All five patients were transferred to another regional 
hospital within 24 h. Effective hemostasis was achieved after treatment 
with PCC in 26 (73%) patients with FXa-I-ICH and 23 (62%) patients 
with VKA-ICH (Fig. 1), corresponding to a crude odds ratio (OR) of 1.62 
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(95%CI 0.59–4.48) (Table 3). After adjustment for age and baseline 
GCS, the adjusted OR for effective hemostasis was 1.45 (95%CI 
0.44–4.83). 
We observed a significant difference in time to presentation be-
tween FXa-I-ICH and VKA-ICH, but could not adjust for this variable, 
because of missing values in 39 (52%) patients. 
We performed four different sensitivity analyses including the five 
patients for whom the efficacy outcome effective hemostasis was 
missing. The first analysis assumed all five patients had poor hemos-
tasis, the second analysis assumed all five patients had effective he-
mostasis, the third analysis assumed all three FXa-I-ICH patients had 
effective hemostasis and both VKA-ICH patients had poor hemostasis, 
and the fourth analysis assumed all three FXa-I-ICH patients had poor 
hemostasis and both VKA-ICH patients had effective hemostasis. The 
results of the sensitivity analyses were not substantially different from 
the original analyses (data not shown). 
3.2.2. Safety 
Thromboembolic events were not assessable due to loss-to-follow up 
in three patients. Two of three patients belonged to the FXa-I-ICH and 
the one to the VKA-ICH. No thromboembolic events occurred within 
30 days after presentation in the FXa-I-ICH cohort and two throm-
boembolic events occurred in the VKA-ICH cohort, hence no OR was 
calculated for thromboembolic events. 
Mortality was not assessable due to loss-to-follow-up in three pa-
tients, of which two belonged to the FXa-I-ICH cohort and the other two 
to the VKA-ICH cohort. Mortality within 30 days was observed in eight 
(24%) patients in the FXa-I-ICH cohort and in 17 (45%) patients in the 
VKA-ICH cohort (Fig. 1). The corresponding crude OR for mortality for 
FXa-I-ICH vs. VKA-ICH was 0.38 (95%CI 0.14–1.24) and the OR ad-
justed for age and baseline GCS was 0.41 (95%CI 0.12–1.42) (Table 3). 
Analogous to the efficacy outcome, we performed four different 
sensitivity analyses including the three patients in which the safety 
outcomes (30-day thrombosis and 30-day mortality) were missing. The 
results of these sensitivity analyses were not substantially different from 
the original analyses (data not shown). 
4. Discussion 
In this study we did not observe a significant difference in hemo-
static efficacy between patients with a direct factor Xa inhibitor related 
Table 1 
Demographic and clinical characteristics at presentation.       
VKA-ICH 
N = 39 
FXa-I-ICH 
N = 36 
p-Value  
Age (years), mean (SD) 73.1 (10.9) 76.1 (8.9)  0.197 
Male, no. (%) 20 (51) 20 (56)  0.771 
Weight (kg), mean (SD)* 81.2 (17.4) 77.1 (14.3)  0.363 
Indication anticoagulant, no. (%)*    
Atrial fibrillation 30 (77) 33 (92)  
Venous thromboembolism 4 (10) 2 (6)  
Mechanical heart valve 2 (5) 0  0.247 
Medical history, no. (%)    
Hypertension 17 (44) 22 (61)  0.129 
Diabetes mellitus 10 (26) 10 (28)  0.834 
Stroke 5 (13) 8 (22)  0.283 
Cancer 4 (10) 6 (17)  0.415 
Thyroid disease 3 (8) 6 (17)  0.232 
Peripheral arterial disease 5 (13) 2 (6)  0.280 
Heart valve disease 2 (5) 3 (8)  0.578 
Concomitant medication use, no. (%)    
Antiplatelet drugs 5 (12.8) 2 (5.6)  0.280 
NSAIDs 3 (8) 1 (3)  0.344  
Bleeding characteristics 
Time from start symptoms to 
presentation (minutes), median 
(IQR)* 
360 (116–1440) 135 (71–253)  0.006 
Systolic blood pressure (mmHg), 
median (IQR)* 
140 (118–171) 156 (139–187)  0.016 
ICH localization, no. (%)    
Intracerebral 16 (33) 14 (39)  
Subdural 11 (23) 6 (17)  0.2 
Subarachnoidal 6 (15) 4 (11)  
Cerebellar 0 5 (14)  
Epidural 1 (3) 1 (3)  
Other 0 1  
Combination 5 (13) 5 (14)  
Trauma, no. (%)* 15 (39) 14 (39)  0.602 
Baseline GCS, median (IQR)* 13 (7–15) 14 (11–15)  0.314 
Volume, median (IQR)*    
Intracerebral bleeding (mL) 22 (3–54) 15 (4–34)  0.695 
Subdural bleeding (mm) 11.7 (4.0–15.3) 11.0 
(10.7–12.0)  
0.958 
VKA: vitamin K antagonist; ICH: intracranial hemorrhage; FXa-I: factor-Xa in-
hibitor; SD: standard deviation, no.: number; kg: kilogram; IQR: interquartile 
range; IU: international units; HVD: heart valve disease; PVD: peripheral ar-
terial disease; TD: thyroid disease; NSAID: non-steroidal anti-inflammatory 
drugs; GCS: Glasgow Coma Scale; mL: mililiter. * Weight was missing in 17 VKA 
patients and 8 FXa-I patients; indication anticoagulant was missing 13 VKA 
patients and 1 FXa-I patient; time to presentation was missing in 24 VKA pa-
tients and 18 FXa-I patients; systolic blood pressure was missing in 2 VKA pa-
tients and 3 FXa-I patients; ICH localization was missing in 5 VKA patients; 
trauma was missing in 13 VKA patients and 3 FXa-I patients; GCS was missing 
in 6 VKA patients and 1 FXa-I patient; volume in mL was missing in 11 VKA 
patients and 12 of the FXa-I patients. ǂ Subclassification for ISTH major 
bleeding according to the severity of bleeding, previously described in methods 
section of this paper.  
Table 2 
Details on ICH course and management.     
ICH course and management VKA-ICH 
N = 39 
FXa-I-ICH 
N = 36  
Dose of PCC (IU/kg), median (IQR)* 20 (20–25) 50 (50-50) 
Total dose of PCC (IU), median (IQR)* 1750 (1250- 
2250) 
3500 (3000-4000) 
Admission intensive care unit, no. (%) 12 (30.8) 11 (30.6) 
Administration packed cells, no. (%)* 2 (5) 0 
Administration of tranexamic acid, no. 
(%) 
0 2 (6) 
Administration of vitamin K, no. (%) 33 (85) N.A. 
Hospital stay (days), median (IQR) 6 (5–12) 7 (3–15) 
Intervention for bleeding, no. (%)* 10 (26) 9 (25) 
VKA: vitamin K antagonist; ICH: intracranial hemorrhage; FXa-I:factor-Xa in-
hibitor; SD: standard deviation, no.: number; kg: kilogram; IQR: interquartile 
range; IU: international units; PCC: prothrombin complex concentrate. * Dose of 
PCC in IU/kg was missing in 14 VKA patients and 2 FXa-I patients; total dose 
PCC was missing in 2 VKA patients; intervention for bleeding was missing in 1 
VKA patient; packed cells was missing in 1 FXa-I patient.  
Fig. 1. Overview of proportion of patients encountering the outcomes, strati-
fied for VKA and FXa-I. 
FXa-I = factor Xa inhibitor; VKA = vitamin K antagonist. 
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intracranial hemorrhage and patients with a vitamin K antagonist re-
lated intracranial hemorrhage treated with PCC, nor in mortality and 
thromboembolic outcomes. Our findings suggest that the prognosis for 
FXa-I-ICH patients managed with PCC does not seem worse than the 
prognosis for VKA-ICH patients treated with PCC. This study does not 
answer the questions if PCC is efficacious and safe for treatment of FXa- 
I-ICH as this would require patients with FXa-I-ICH that did not receive 
PCC. However, in an observational study such as the present one this 
would lead to considerable confounding by indication which cannot be 
reliably adjusted for. We therefore chose to compare with VKA-ICH 
since a specific reversal agent has been available for VKAs for years, and 
both cohorts represent a similarly urgent clinical situation in which the 
use of a reversal agent is deemed necessary. 
Our findings can be interpreted in different ways. First, these find-
ings could suggest that PCC is an effective reversal agent for FXa-I. This 
is plausible as PCC contains coagulation factor X which, after activation 
at the site of bleeding may compete with the circulating FXa-I and re-
store thrombin generation sufficiently to control bleeding. This inter-
pretation is supported by our recent study showing that PCC swiftly 
increases endogenous thrombin potential in patients with a FXa-I re-
lated major bleeding, which is also in line with previous studies in 
healthy volunteers [13,20]. Secondly, our findings could also suggest 
that PCC does not improve effective hemostasis for both FXa-I-ICH and 
VKA-ICH. In ICH, the prognosis of the bleed may be determined mostly 
before presentation to the emergency room and not so much by the 
strategy to restore functional hemostasis [21]. This interpretation is 
supported by the results of the trial randomizing patients with a major 
VKA related bleeding to either PCC or fresh frozen plasma, demon-
strating swift INR reversal did not influence effective hemostasis [19]. 
Thirdly, these findings could also be explained by a different prognosis 
between FXa-I-ICH and VKA-ICH, in our study or in general. In our 
study we observed a significant difference in time to presentation 
(135 min in the FXa-I-ICH cohort vs. 360 min in the VKA-ICH cohort, 
p = 0.006). However, we were not able to adjust for this difference in 
our multivariate model as this variable was missing in 52% of the pa-
tients. We do not have a plausible explanation for this finding, other 
than chance, but we cannot rule out that this partially explains our 
findings. It is also possible that there is an intrinsic difference in 
prognoses of FXa-I-ICH and VKA-ICH, determined by differences in 
other factors such as baseline hematoma volume. Consequently, the 
prognosis of FXa-I-ICH may be better than VKA-ICH and balance out the 
disadvantage of the lack of specific reversal agents. This is plausible as 
the majority of published studies within this field implies that DOAC- 
ICH may have smaller volumes and hence better prognoses in com-
parison with VKA-ICH [22–24]. 
Strengths of this study are that both the FXa-I cohort and the VKA- 
cohort are contemporary and had identical inclusion criteria, clinical 
outcome definitions and follow-up. Moreover, the primary outcome 
“effective hemostasis” for both cohorts was according to the ISTH de-
finition, which is considered the benchmark for studies evaluating the 
efficacy of reversal agents [17,20,25–27]. Some limitations of our study 
warrant consideration. The main limitation is the observational nature 
of this study by which we cannot establish the true efficacy and safety 
of PCC in FXa-I-ICH. Our observations can only be interpreted as as-
sociations of FXa-I-ICH and VKA-ICH treated with PCC with the clinical 
outcomes and do not evince a causal pathway as we cannot account for 
uncontrolled confounders, such as the oral anticoagulant preference of 
the initial prescriber and time period in which the patients were in-
cluded. We realize that for evaluating the efficacy and safety of PCC in 
patients with FXa-I-ICH a randomized controlled trial (RCT) would be 
necessary. However, by using a multiple regression model with ad-
justment for measured confounders such as age and baseline GCS, we 
minimized the potentially induced bias by these confounders. A second 
limitation is the relatively small number of patients that was included in 
this study. One could argue that due to lack of statistical power we did 
not detect significant differences in outcome variables between the two 
cohorts. However, the calculated 95% confidence intervals around the 
point estimates (hemostatic efficacy, mortality) in the FXa-I cohort and 
the VKA-ICH overlap substantially and we therefore believe that this 
limitation does not preclude our conclusions. Furthermore, we did not 
adjust for potential confounders with more than 30% missing values, 
such as hematoma volume and time from start of symptoms to pre-
sentation. To counterbalance this limitation, we performed regression 
analyses in two different ways and performed sensitivity analyses, as 
described in the method section. These additional analyses did not 
change the main conclusions of this study. Unfortunately no informa-
tion was collected on the renal insufficiency. 
Now that andexanet alfa is approved for reversal of rivaroxaban and 
apixaban in patients with life-threatening bleeding, the American 
Society of Hematology guideline recommends either PCC or 
andexanet alfa for FXa-I reversal [9]. Our study design does not allow 
for a comparative efficacy and safety analysis between PCC and the 
recently approved specific antidote andexanet alfa. Indirect compar-
isons between the subgroup FXa-I-ICH in two cohorts managed with 
PCC and one cohort managed with andexanet alfa (ANNEXA-4) yields 
effective hemostasis rates according to the ISTH definition of 72.8%, 
83.3% and 80.4%, respectively [25–27]. The comparison of these two 
agents in a randomized trial is relevant as andexanet alfa is much more 
expensive than PCC. Currently an RCT is ongoing in patients with an 
FXa-I-ICH in which the efficacy and safety of andexanet alfa is 
Table 3 
Efficacy and safety outcomes per treatment group in the bleeding population after administration of PCC.        
Efficacy outcome, no. (%, 95% CI) FXa-I 
(n = 36) 
VKA 






(95% CI)  









(0.44–4.83)         
Safety outcomes, no. (%, 95% CI) FXa-I 
(n = 36) 
VKA 






(95% CI)  
30-day thromboembolic rate 0 
N.A. 
2 
(5%, 2%–17%)  N.A.  N.A.  N.A 










95% CI = 95% confidence interval; VKA = vitamin K antagonist; FXa-I = factor Xa inhibitor; OR = odds ratio; n = number; N.A. = not applicable. 
In 5 patients (2 VKA and 3 FXa-I) effective hemostasis was not assessable. For 30-day thromboembolic events there is 1 missing value for VKA and 2 for throm-
boembolic events. For mortality 1 value is missing in the VKA cohort and 2 values are missing in FXa-I cohort. 
⁎ Odds ratio adjusted for age, baseline GCS (missing in 4 patients) and type ICH (intracerebral vs non-intracerebral). This model was based on clinical reasoning. 
⁎⁎ Odds ratio for when adjusted for age and baseline GCS (missing in four patients). This model was based on selecting associations with a p-values < 0.25.  
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compared with usual care (trialregister.gov; NCT03661528). The ex-
pectation is that PCC will be opted as standard of usual care in the 
majority of the patients randomized to the ‘usual of care’ arm and 
therefore in this study, andexanet alfa will likely be compared with 
PCC. Until this trial establishes what the optimal reversal strategy for 
FXa-I-ICH is, our study suggests that if PCC is used for management of 
FXa-I-ICH, the prognosis will not be worse than what we have come to 
know from patients with VKA-ICH reversal [28]. 
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